Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

miR-519a-3p, found to regulate cellular prion protein during Alzheimer's disease pathogenesis, as a biomarker of asymptomatic stages

  • Jácome, Dayaneth
  • Cotrufo, Tiziana
  • Andrés-Benito, P.|||0000-0003-3000-0338
  • Lidón Gil, Laia|||0000-0002-2083-3515
  • Martí, Eulàlia|||0000-0002-1030-3158
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Rio, Jose Antonio del|||0000-0002-5214-4909
  • Gavín, Rosalina|||0000-0003-1982-2162
Clinical relevance of miRNAs as biomarkers is growing due to their stability and detection in biofluids. In this, diagnosis at asymptomatic stages of Alzheimer's disease (AD) remains a challenge since it can only be made at autopsy according to Braak NFT staging. Achieving the objective of detecting AD at early stages would allow possible therapies to be addressed before the onset of cognitive impairment. Many studies have determined that the expression pattern of some miRNAs is dysregulated in AD patients, but to date, none has been correlated with downregulated expression of cellular prion protein (PrP) during disease progression. That is why, by means of cross studies of miRNAs up-regulated in AD with in silico identification of potential miRNAs-binding to 3'UTR of human PRNP gene, we selected miR-519a-3p for our study. Then, in vitro experiments were carried out in two ways. First, we validated miR-519a-3p target on 3'UTR-PRNP, and second, we analyzed the levels of PrP expression after using of mimic technology on cell culture. In addition, RT-qPCR was performed to analyzed miR-519a-3p expression in human cerebral samples of AD at different stages of disease evolution. Additionally, samples of other neurodegenerative diseases such as other non-AD tauopathies and several synucleinopathies were included in the study. Our results showed that miR-519a-3p overlaps with PRNP 3'UTR in vitro and promotes downregulation of PrP. Moreover, miR-519a-3p was found to be up-regulated exclusively in AD samples from stage I to VI, suggesting its potential use as a novel label of preclinical stages of the disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human induced pluripotent stem cell-derived myotubes to model inclusion body myositis

  • Cantó-Santos, Judith|||0000-0002-0272-7014
  • Valls-Roca, Laura|||0000-0001-5956-6752
  • Tobías, Ester|||0000-0002-9968-3651
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Guitart-Mampel, Mariona
  • Andújar-Sánchez, Félix
  • Vilaseca-Capel, Adrià
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Martín-Mur, Beatriz|||0000-0002-6006-3295
  • Padrosa, Joan
  • Peruga, Emma
  • Madrigal, Irene|||0000-0002-7229-1199
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José Carlos
  • Moreno-Lozano, Pedro J.
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Sevilla, Ana|||0000-0002-9251-4759
  • Milisenda, José César|||0000-0003-0151-7872
  • Garrabou, Glòria|||0000-0001-8973-9933
Inclusion body myositis (IBM) is an inflammatory myopathy that displays proximal and distal muscle weakness. At the histopathological level, the muscles of IBM patients show inflammatory infiltrates, rimmed vacuoles and mitochondrial changes. The etiology of IBM remains unknown, and there is a lack of validated disease models, biomarkers and effective treatments. To contribute to unveil disease underpins we developed a cell model based on myotubes derived from induced pluripotent stem cells (iPSC-myotubes) from IBM patients and compared the molecular phenotype vs. age and sex-paired controls (n = 3 IBM and 4 CTL). We evaluated protein histological findings and the gene expression profile by mRNA-seq, alongside functional analysis of inflammation, degeneration and mitochondrial function. Briefly, IBM iPSC-myotubes replicated relevant muscle histopathology features of IBM, including aberrant expression of HLA, TDP-43 and COX markers. mRNA seq analysis identified 1007 differentially expressed genes (DEGs) (p-value adj < 0.01; 789 upregulated and 218 downregulated), associated with myopathy, muscle structure and developmental changes. Among these, 1 DEG was related to inflammation, 28 to autophagy and 28 to mitochondria. At the functional level, inflammation was similar between the IBM and CTL groups under basal conditions (mean cytokine expression in IBM 4.6 ± 1.4 vs. 6.7 ± 3.4 in CTL), but increased in IBM iPSC-myotubes after lipopolysaccharide treatment (72.5 ± 21.8 in IBM vs. 13.0 ± 6.7 in CTL). Additionally, autophagy was disturbed, with 40.14% reduction in autophagy mediators. Mitochondrial dysfunction was strongly manifested, showing a conserved respiratory profile and antioxidant capacity, but a 56.33% lower cytochrome c oxidase/citrate synthase ratio and a 66.59% increase in lactate secretion. Overall, these findings support patient-derived iPSC-myotubes as a relevant model for IBM, reflecting the main muscle hallmarks, including inflammation, autophagy dysfunction and mitochondrial alterations at transcriptomic, protein and functional levels.